NCT07474779Toborzás még nem indult
Understanding Alpha-Synuclein Spread in Parkinson's Disease Through Blood Biomarkers and Neuroimaging
From Genes to Virtual Brain: Defining the Pathogenic Mechanisms Promoting Alfa-synuclein Seeding and Spreading in Parkinson's Disease.
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. máj. 1.
Rövid összefoglaló (regiszter, angolul)
The project aims to investigate how abnormal accumulation of alpha synuclein and its interaction with tau influence brain function across the Parkinson's disease (PD) spectrum, with particular focus on individuals carrying GBA1 mutations. This interventional, monocentric, cross sectional study includes patients with PD, individuals with idiopathic REM sleep behavior disorder, and participants without PD. All enrolled subjects will undergo clinical and neuropsychological assessments, blood based biomarker analyses related to neurodegeneration, synaptic and mitochondrial function, and multimodal brain MRI to evaluate brain structure, white matter integrity, and functional connectivity. The study aims to: * characterize the relationship between alpha synuclein/tau pathology and synaptic mitochondrial dysfunction; * identify biomarker and connectivity signatures across disease stages and genetic backgrounds; * integrate preclinical, clinical, biological, and imaging data to support the development of mechanistic models of alpha synuclein propagation. In parallel, preclinical studies in GBA PD mouse models and wild type mice will be used to investigate how changes in PD-related pathology (alpha-synuclein and tau) relates to behavior, brain imaging alterations and mitochondrial, axonal and synaptic damage. Animal model will also aid the validation of a new PET tracer that targets alpha synuclein (i.e., [¹⁸F]Syntacasyn). Together, human and preclinical studies are designed to provide a translational framework integrating molecular changes with brain network alterations and clinical heterogeneity in PD.
- Állapot (regiszter)
- Toborzás még nem indult
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 160 (tervezett)
- Első benyújtás
- 2026. márc. 6.
- Kezdés
- 2026. máj. 11.
- Elsődleges befejezés
- 2028. dec.
- Fő szponzor
- University of Pavia
- Betegségek
- Parkinson-kór
- NCT-szám
- NCT07474779
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 160
- 2026. máj. 11. és az elsődleges befejezés (2028. dec.) között
- 2 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Diagnosis of dementia according to DSM-5 criteria;
- Presence of other neurological disorders and/or essential tremor;
- Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment.
- Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;
- Diagnosis of dementia according to DSM-5 criteria.
- Presence of systemic inflammatory or infectious diseases, autoimmune diseases, or malignant tumors at the time of enrollment;
- Diagnosis of dementia according to DSM-5 criteria.
Egyéb
- Diagnosis of atypical and/or secondary parkinsonism;
- Diagnosis of atypical and/or secondary parkinsonism;
- Diagnosis of atypical and/or secondary parkinsonism;
Kiket keres a vizsgálat
- Diagnosis of PD according to MDS-PD criteria and, for the GBA-PD group, presence of heterozygous GBA mutations (with a balanced distribution of severe, risk, mild, and complex variants);
- Disease duration between 3 and 7 years;
- Disease stage according to Hoehn \& Yahr ≤ 3;
- Absence of mutations in other known genes associated with PD susceptibility;
- Age > 18 Years;
- Ability to understand and voluntarily sign informed consent and to comply with study procedures.
- Age > 18 Years;
- Ability to understand and voluntarily sign informed consent and to comply with study procedures;
- No diagnosis of PD or other neurological disorders;
- Presence of a heterozygous GBA mutation for the GBA-nonPD group and absence of such mutation for control subjects (nonGBA-nonPD);
- Absence of mutations in other known genes associated with PD susceptibility.
- Diagnosis of idiopathic REM Sleep Behavior Disorder according to ICSD-3;
- Age > 18 Years;
- Ability to understand and voluntarily sign informed consent and to comply with study procedures;
- No diagnosis of PD or other neurological disorders;
- Presence of a heterozygous GBA mutation for the GBA-iRBD group and absence of such mutation for the nonGBA-iRBD group;
- Absence of mutations in other known genes associated with PD susceptibility.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (2)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Neurological Institute Foundation Casimiro Mondino | Pavia | Olaszország | Ismeretlen állapot |
| University of Pavia | Pavia | Olaszország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.